Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?
Zacks Investment Research | Jan 22, 2020 09:01PM ET
Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reached a new 52-week high of $151.70 on Jan 22, closing the session marginally lower at $150.98. The stock has rallied 7.8% since its third-quarter 2019 earnings announcement on Nov 5.
The company’s strong third-quarter earnings results, backed by robust segmental and global revenue growth, prompted the rally. Currently, the company is reinforcing its focus toward enabling technology to provide a complete customer and patient-centric ecosystem.
Let us delve deeper.
Q3 Performance
Zimmer exited the third quarter on a strong note, with better-than-expected earnings and revenue numbers. It witnessed year-over-year improvements in revenues in the majority of its segments as well as across EMEA and the Asia Pacific.
Zimmer is upbeat about continuing the recent trend in the EMEA and the Asia Pacific in the upcoming quarters as well on product launches and strong customer adoptions. Despite a rise in the cost of products sold, the company registered gross margin improvement on solid top-line performance. This also buoyed investors’ optimism.
Other Growth Drivers
Approvals and Product Launches: Investors seem to be upbeat about Zimmer as it provides some top-of-the-line products in the industry. Strong adoption of its products like Persona Revision Knee System, commercially launched in September 2019, The Tether for treatment of scoliosis, and the FDA-cleared JuggerStitch meniscal repair device and ROSA ONE Spine System is a key catalyst.
The company’s mymobility digital health platform (developed in partnership with Apple (NASDAQ:AAPL) in October 2018), and the major launch of flagship products like Persona Partial and Persona Cementless instill optimism as well.
Partnership: Zimmer signed a multinational distribution agreement with Align (NASDAQ:ALGN) Technology with respect to the iTero Element family of intraoral scanners. The agreement is expected to expand Zimmer’s footprint in the global digital restorative dentistry solutions market.
Execution of Growth Plans: The company is progressing well with the quality remediation in the North Campus, which it initiated in the third quarter of 2019. Completion of the detailed remediation plan on the Warsaw North campus is currently part of Zimmer’s pipeline.
Get The News You Want
Additionally, the company is gaining from the global rollout of the Quality Begins With Me program, which is focused on driving sustainable quality culture. Zimmer is increasingly focusing on innovations in enabling technology, regarding implants such as robotics and mini robotics, and informatics and operating room efficiency.
Zacks Rank & Key Picks
Currently, the company carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , Hill-Rom Holdings, Inc. (NYSE:HRC) and Myomo, Inc. (NYSE:MYO) .
Haemonetics currently sports a Zacks Rank #1 (Strong Buy) and has a projected long-term earnings growth rate of 13.5%. You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.